Form 4: TECX CSO Exercises Stock Options

Tectonic Therapeutic's Chief Scientific Officer, Peter McNamara, exercised 7,000 employee stock options at $2.98 per share.

Summary

• Peter McNamara, Chief Scientific Officer of Tectonic Therapeutic, Inc. (TECX), exercised 7,000 employee stock options.
• The transaction occurred on December 22, 2025.
• The exercise price for the common stock was $2.98 per share.
• Following this transaction, McNamara directly owns 40,879 shares of common stock.
• He also directly holds 25,065 employee stock options with an exercise price of $2.98, which are set to expire on June 26, 2032.
• The remaining options were received in exchange for a stock option to acquire 60,000 shares of common stock pursuant to a merger, as previously described in a Form 4 filed on June 24, 2024.
• The shares subject to the exercised option vested in 48 equal monthly installments beginning on June 27, 2022, contingent on continued service to the Issuer.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. An executive exercising options is generally a positive signal of confidence, but this is a routine transaction and not indicative of major news. The exercise price is low, suggesting the options are in-the-money.

Positives

• An executive exercising options can signal confidence in the company's future prospects, as they are increasing their direct equity stake.
• The exercise price of $2.98 per share indicates the options were in-the-money, suggesting a potential gain for the executive and implying the stock price is above this level.

Future Outlook

This filing is a report of an insider transaction and does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

Insider transactions, such as option exercises, are common in the biotechnology and pharmaceutical industries, where equity compensation is a significant component of executive remuneration. Such transactions are typically viewed by the market as routine unless they involve unusually large volumes or are part of a broader pattern of insider buying or selling that could signal a change in management's outlook.

Comparison to Industry Standards

• This Form 4 reports a standard insider transaction (option exercise) and does not provide data for direct comparison to specific industry benchmarks or competitor results.
• The exercise price of $2.98 is a contractual term of the option grant, not a market performance metric for industry comparison.

Related Party Transactions

• The option exercise is a transaction between an executive and the company, which is a form of related party transaction, but it is a standard compensation event rather than an unusual dealing.

Stakeholder Impact

• Shareholders: May view the executive's option exercise as a sign of confidence, potentially influencing sentiment.
• Employees: Confirms the ongoing standard practice of equity compensation for executives.

Key Dates

Recommendation

This Form 4 reports a routine insider transaction where the Chief Scientific Officer exercised employee stock options. While an executive exercising options can be a minor positive signal of confidence, it does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. The transaction is a standard part of executive compensation and does not indicate a significant shift in the company's outlook or valuation.

Keywords

Tectonic Therapeutic, TECX, Stock Option Exercise, Insider Transaction, Peter McNamara, Chief Scientific Officer, Form 4, Equity Compensation